MD Anderson and Jazz Pharmaceuticals collaborate on AML research

The University of Texas MD Anderson Cancer Center and Ireland-incorporated Jazz Pharmaceuticals (Nasdaq: JAZZ)  late Monday announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.

The joint effort brings together MD Anderson's translational medicine and clinical research capabilities with Jazz’s hematology/oncology portfolio, including its Food and Drug Administration-approved medicines as well as current and potential future investigational therapies. No financial terms have been revealed.

“This collaboration represents a significant opportunity to efficiently develop innovative therapies and therapeutic combinations,” said Dr Tapan Kadia, associate professor of Leukemia at MD Anderson, adding: “Our aim is to always provide leading-edge care for our leukemia patients, and it is our hope that this joint effort will result in new treatment solutions.”